Latest & greatest articles for nivolumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nivolumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nivolumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nivolumab

1. Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy)

Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy) Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy) | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies (...) . This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy) Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy) July 2017 Nivolumab is a drug which blocks a protein, called the programmed death-1 (PD-1) receptor, on the surface of certain immune cells

2017 NIHR Innovation Observatory

2. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation

Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested (...) could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Cabozantinib is likely to be the best treatment to delay tumour growth and prolong life, followed by nivolumab, but all treatments delayed disease progression and prolonged survival compared with best supportive care. {{author}} {{($index , , , , , , & . Steve J Edwards

2018 NIHR HTA programme

3. Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy Niv Nivolumab for treating squamous cell olumab for treating squamous cell carcinoma of the head and neck after carcinoma of the head and neck after platinum-based chemother platinum-based chemotherap apy y T echnology appraisal guidance Published: 22 November 2017 nice.org.uk/guidance/ta490 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms (...) due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490) © NICE 2019. All rights reserved

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

4. [Nivolumab for the treatment of advanced melanoma]

[Nivolumab for the treatment of advanced melanoma] [Nivolumab for the treatment of advanced melanoma] [Nivolumab for the treatment of advanced melanoma] González L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation González L, Pichon-Riviere A, Augustovski F (...) , García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Nivolumab for the treatment of advanced melanoma] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 543. 2017 Authors' conclusions High quality evidence showed that the use of nivolumab as first-line therapy, in patients with advanced (metastatic or irresecable) melanoma without BRAF mutations would increase the rate of one year progression

2017 Health Technology Assessment (HTA) Database.

5. Nivolumab (Opdivo) for recurrent or metastatic squamous cell carcinoma of the head and neck - second line

Nivolumab (Opdivo) for recurrent or metastatic squamous cell carcinoma of the head and neck - second line Nivolumab (Opdivo) for recurrent or metastatic squamous cell carcinoma of the head and neck – second line Nivolumab (Opdivo) for recurrent or metastatic squamous cell carcinoma of the head and neck – second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation NIHR HSRIC. Nivolumab (Opdivo) for recurrent or metastatic squamous cell carcinoma of the head and neck – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Head and neck cancer is a rare type of cancer. There are over 30 areas in the head and neck where the cancer can develop, for example, the mouth, nose, sinuses and throat. Tobacco smoking and alcohol are known to increase the risk of developing head

2015 Health Technology Assessment (HTA) Database.

6. [Nivolumab (renal cell carcinoma) - addendum to commission A16-24]

[Nivolumab (renal cell carcinoma) - addendum to commission A16-24] Nivolumab (nierenzellkarzinom): addendum zum auftrag A16-24; auftrag A16-56 [Nivolumab (renal cell carcinoma) - addendum to commission A16-24] Nivolumab (nierenzellkarzinom): addendum zum auftrag A16-24; auftrag A16-56 [Nivolumab (renal cell carcinoma) - addendum to commission A16-24] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (nierenzellkarzinom): addendum zum auftrag A16-24; auftrag A16-56. [Nivolumab (renal cell carcinoma) - addendum to commission A16-24] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 438. 2016 Final publication URL Indexing Status

2017 Health Technology Assessment (HTA) Database.

7. Nivolumab (Opdivo©) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)

Nivolumab (Opdivo©) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) Grössmann N Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Grössmann N. Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology. 2017 Authors' conclusions The treatment of nivolumab offers durable responses, 31.1% demonstrated

2017 Health Technology Assessment (HTA) Database.

8. Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients

Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03081689 Recruitment Status : Active, not recruiting First Posted : March 16, 2017 Last Update Posted : November 14, 2018 Sponsor: Spanish Lung Cancer Group

2017 Clinical Trials

9. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. (PubMed)

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma.We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 (...) weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end points were overall survival (alpha level, 0.04), objective response rate (alpha level, 0.001), and progression-free survival (alpha level, 0.009) among patients with intermediate or poor prognostic risk.A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib (546 patients); 425 and 422

Full Text available with Trip Pro

2018 NEJM

10. Nivolumab (Opdivo) Metastatic Melanoma - Details

Nivolumab (Opdivo) Metastatic Melanoma - Details Opdivo for Metastatic Melanoma - Details | CADTH.ca Find the information you need Opdivo for Metastatic Melanoma - Details Opdivo for Metastatic Melanoma - Details Project Number pCODR 10063 Brand Name Opdivo Generic Name Nivolumab Strength 40mg/4mL and 100mg/10mL vials Tumour Type Skin and Melanoma Indication Metastatic Melanoma Funding Request For the treatment of both first-line and previously-treated advanced adult melanoma patients (...) has been granted for nivolumab (Opdivo). In accordance with the pCODR Procedures, the pCODR Provincial Advisory Group (PAG) requested additional information on nivolumab (Opdivo) which extends beyond the submitted scope of the review. Revision of review scope may be considered by pCODR in very limited instances, based on jurisdictional input, feasibility to conduct the revised review and clinical importance. All three criteria for scope modification were met in this case. The timeline

2015 CADTH - Pan Canadian Oncology Drug Review

11. Nivolumab for previously treated non-squamous non-small-cell lung cancer

Nivolumab for previously treated non-squamous non-small-cell lung cancer Niv Nivolumab for pre olumab for previously treated non- viously treated non- squamous non-small-cell lung cancer squamous non-small-cell lung cancer T echnology appraisal guidance Published: 1 November 2017 nice.org.uk/guidance/ta484 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 34Contents Contents 1

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

12. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma Niv Nivolumab for treating relapsed or olumab for treating relapsed or refr refractory classical Hodgkin lymphoma actory classical Hodgkin lymphoma T echnology appraisal guidance Published: 26 July 2017 nice.org.uk/guidance/ta462 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 28Contents Contents 1

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

13. [Nivolumab (squamous cell carcinoma of the head and neck) - benefit assessment according to õ35a Social Code Book V]

[Nivolumab (squamous cell carcinoma of the head and neck) - benefit assessment according to õ35a Social Code Book V] Nivolumab (Plattenepithelkarzinom des Kopf-Hals-Bereichs): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [Nivolumab (squamous cell carcinoma of the head and neck) - benefit assessment according to §35a Social Code Book V] Nivolumab (Plattenepithelkarzinom des Kopf-Hals-Bereichs): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [Nivolumab (squamous cell carcinoma (...) of the head and neck) - benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab (Plattenepithelkarzinom des Kopf-Hals-Bereichs): Nutzenbewertung gemäß § 35a SGB

2017 Health Technology Assessment (HTA) Database.

14. Nivolumab for the treatment of non-small cell lung cancer

Nivolumab for the treatment of non-small cell lung cancer Nivolumab for the treatment of non-small cell lung cancer Nivolumab for the treatment of non-small cell lung cancer Oubiña M, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Oubiña M, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L. Nivolumab for the treatment of non-small cell lung cancer. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 479. 2016 Authors' conclusions The evidence on the effectiveness and safety of nivolumab as second line treatment for advanced non-small cell lung cancer, compared with docetaxel is of high quality. Nivolumab was associated

2017 Health Technology Assessment (HTA) Database.

15. Nivolumab for the treatment of renal-cell carcinoma

Nivolumab for the treatment of renal-cell carcinoma Nivolumab for the treatment of renal-cell carcinoma Nivolumab for the treatment of renal-cell carcinoma Soto N, López A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Soto N, López A, Pichon (...) -Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, Rey-Ares L. Nivolumab for the treatment of renal-cell carcinoma. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 491. 2016 Authors' conclusions No evidence has been identified on the use of nivolumab as first-line treatment or in localized renal-cell carcinoma stage. High-quality evidence, coming from a single study in patients with clear cell histology, indicates

2016 Health Technology Assessment (HTA) Database.

16. Nivolumab (squamous cell carcinoma of the head and neck) - Addendum to Commission A17-24

Nivolumab (squamous cell carcinoma of the head and neck) - Addendum to Commission A17-24 1 Translation of addendum A17-54 Nivolumab (Plattenepithelkarzinom des Kopf-Hals-Bereichs) – Addendum zum Auftrag A17-24 (Version 1.0; Status: 25 October 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 25 October 2017 1.0 Commission: A17-54 Version: Status (...) : IQWiG Reports – Commission No. A17-54 Nivolumab (squamous cell carcinoma of the head and neck) – Addendum to Commission A17-24 1 Addendum A17-54 Version 1.0 Nivolumab – Addendum to Commission A17-24 25 October 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (squamous cell carcinoma of the head and neck) – Addendum to Commission A17-24 Commissioning agency: Federal Joint Committee

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

17. Nivolumab (Nivolumab BMS©) for the second-line therapy of metastatic squamous non-small cell lung cancer

Nivolumab (Nivolumab BMS©) for the second-line therapy of metastatic squamous non-small cell lung cancer Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA). Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). Decision Support Document: Horizon Scanning in Oncology No. 53. 2015 Authors' conclusions Nivolumab is the first immunotherapy medicine licensed in the European

2015 Health Technology Assessment (HTA) Database.

18. Nivolumab (Opdivo) for treatment of non-small cell lung cancer

Nivolumab (Opdivo) for treatment of non-small cell lung cancer Nivolumab (Opdivo) for treatment of non-small cell lung cancer Nivolumab (Opdivo) for treatment of non-small cell lung cancer HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Nivolumab (Opdivo) for treatment of non-small cell lung cancer. Lansdale: HAYES, Inc.. Healthcare (...) Technology Brief Publication. 2016 Authors' conclusions Description of Technology: Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to programmed death (PD-1) pathway that is active in non-small cell lung cancer (NSCLC). Nivolumab inhibits PD-1, preventing it from interacting with its ligands and permitting activated T cells to attack tumor cells. Patient Population: Nivolumab is indicated for the treatment of metastatic NSCLC in patients with progression on or after platinum-based

2016 Health Technology Assessment (HTA) Database.

19. Opdivo (nivolumab)

Opdivo (nivolumab) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 15 September 2017 EMA/586431/2017 EMEA/H/C/003985/II/29 Questions and answers Withdrawal of the application for a change to the marketing authorisation for Opdivo (...) (nivolumab) On 20 July 2017, Bristol-Myers Squibb Pharma EEIG officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a new use of Opdivo in the treatment of liver cancer. What is Opdivo? Opdivo is a cancer medicine that contains the active substance nivolumab and is available as a concentrate that is made up into a solution for infusion (drip) into a vein. Opdivo has been authorised since June 2015. It is already used for advanced

2017 European Medicines Agency - EPARs

20. Nivolumab (Opdivo) - to treat stomach cancer, including cancers that occur at the junction of the stomach and oesophagus

Nivolumab (Opdivo) - to treat stomach cancer, including cancers that occur at the junction of the stomach and oesophagus 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 27 July 2018 EMA/504630/2018 EMEA/H/C/003985/II/0039 (...) Withdrawal of application for a change to the marketing authorisation for Opdivo (nivolumab) On 27 June 2018, Bristol-Myers Squibb Pharma EEIG officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a new use of Opdivo for the treatment of stomach cancer. What is Opdivo? Opdivo is a cancer medicine currently authorised to treat the following cancers: melanoma (skin cancer), non-small cell lung cancer, renal cell carcinoma (kidney cancer

2018 European Medicines Agency - EPARs